Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...
The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...
Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...
However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...
Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...
Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...
AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback